Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD

Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD

Introduction: Chronic inflammation is the core mechanism of the development of chronic obstructive pulmonary disease (COPD). Corticosteroid resistance in COPD limits its anti-inflammatory potency. p38 MAPKIs were suggested as an alternative to corticosteroids despite the fact that there is currently...

Full description

Bibliographic Details
Main Authors: Haichuan Yu, Xiaojie Su, Ting Lei, Lu Zhang, Zhouzhou Feng, Chuchu Zhang, Meng Zhang, Yalei Wang, Xinlong Chen, Jian Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
COPD
systematic review
meta-analysis
p38 MAPK
safety
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.950035/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.950035/full

Similar Items